18 August 2017Americas

Mylan finalises $465m settlement with US government

Mylan has finalised a $465 million payment to the US government to settle a lawsuit about the classification of EpiPen Auto-Injector (epinephrine) under the Medicaid Drug Rebate Program.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
11 October 2016   Mylan has agreed to pay the US Department of Justice and other government agencies $465 million to settle questions about the classification of EpiPen Auto-Injector under the Medicaid Drug Rebate Program.
Americas
17 August 2018   The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions.

More on this story

Americas
11 October 2016   Mylan has agreed to pay the US Department of Justice and other government agencies $465 million to settle questions about the classification of EpiPen Auto-Injector under the Medicaid Drug Rebate Program.
Americas
17 August 2018   The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions.

More on this story

Americas
11 October 2016   Mylan has agreed to pay the US Department of Justice and other government agencies $465 million to settle questions about the classification of EpiPen Auto-Injector under the Medicaid Drug Rebate Program.
Americas
17 August 2018   The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions.